Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1992 Jan;47(1):6–13. doi: 10.1136/thx.47.1.6

Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

S S Pedersen 1, N Høiby 1, F Espersen 1, C Koch 1
PMCID: PMC463537  PMID: 1539148

Abstract

BACKGROUND: Chronic bronchopulmonary infection with mucoid, alginate producing Pseudomonas aeruginosa occurs characteristically in patients with cystic fibrosis. Alginate may be a virulence factor for P aeruginosa infection in such patients. METHODS: Forced vital capacity (FVC), nutritional state and the antibody response to P aeruginosa were determined at regular intervals from three years before chronic P aeruginosa infection to 10 years afterwards in 73 patients with cystic fibrosis. All patients were treated intensively with antipseudomonal chemotherapy during the study period. RESULTS: FVC was reduced in all patients who subsequently developed P aeruginosa infection before they acquired the infection, indicating significant pre-existing lung damage when compared with patients who remained free of P aeruginosa. Lung function and nutritional state remained unchanged after 10 years of infection, except in the patients who died of P aeruginosa lung infection. The FVC and height and weight of patients infected with nonmucoid strains of P aeruginosa were similar to those of uninfected patients. Patients infected with mucoid strains had poorer lung function and nutritional state for the first five years after infection compared with patients with nonmucoid strains. Such infection was also associated with greater IgG and IgA antibody responses to P aeruginosa standard antigen compared with nonmucoid infection. Concentrations of antibody to alginate were similar in patients with non-mucoid and mucoid infection. Noticeably increased concentrations of IgA antibodies to P aeruginosa standard antigen were observed early after the onset of infection in patients who subsequently died. CONCLUSION: Alginate producing P aeruginosa infection is associated with a hyperimmune response and poor clinical condition, suggesting that alginate production is a virulence factor in such infections in patients with cystic fibrosis.

Full text

PDF
8

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anastassiou E. D., Mintzas A. C., Kounavis C., Dimitracopoulos G. Alginate production by clinical nonmucoid Pseudomonas aeruginosa strains. J Clin Microbiol. 1987 Apr;25(4):656–659. doi: 10.1128/jcm.25.4.656-659.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andersen E., Hutchings B., Jansen J., Nyholm M. Højde og vaegt hos danske børn. Ugeskr Laeger. 1982 Jun 14;144(24):1760–1765. [PubMed] [Google Scholar]
  3. Brett M. M., Ghoneim A. T., Littlewood J. M. Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: a follow-up study. J Clin Microbiol. 1988 Aug;26(8):1565–1570. doi: 10.1128/jcm.26.8.1565-1570.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burns M. W., May J. R. Bacterial precipitins in serum of patients with cystic fibrosis. Lancet. 1968 Feb 10;1(7537):270–272. doi: 10.1016/s0140-6736(68)90121-9. [DOI] [PubMed] [Google Scholar]
  5. Corey M., Levison H., Crozier D. Five- to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis. 1976 Dec;114(6):1085–1092. doi: 10.1164/arrd.1976.114.6.1085. [DOI] [PubMed] [Google Scholar]
  6. Doggett R. G., Harrison G. M. Pseudomonas aeruginosa: immune status in patients with cystic fibrosis. Infect Immun. 1972 Oct;6(4):628–635. doi: 10.1128/iai.6.4.628-635.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Henry R. L., Dorman D. C., Brown J., Mellis C. Mucoid Pseudomonas aeruginosa in cystic fibrosis. Aust Paediatr J. 1982 Mar;18(1):43–45. doi: 10.1111/j.1440-1754.1982.tb01979.x. [DOI] [PubMed] [Google Scholar]
  8. Hoiby N., Flensborg E. W., Beck B., Friis B., Jacobsen S. V., Jacobsen L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis. 1977 Apr;58(2):65–79. [PubMed] [Google Scholar]
  9. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):551–558. [PubMed] [Google Scholar]
  10. Høiby N., Döring G., Schiøtz P. O. The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol. 1986;40:29–53. doi: 10.1146/annurev.mi.40.100186.000333. [DOI] [PubMed] [Google Scholar]
  11. Johnson K. J., Wilson B. S., Till G. O., Ward P. A. Acute lung injury in rat caused by immunoglobulin A immune complexes. J Clin Invest. 1984 Aug;74(2):358–369. doi: 10.1172/JCI111431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kerem E., Corey M., Gold R., Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr. 1990 May;116(5):714–719. doi: 10.1016/s0022-3476(05)82653-8. [DOI] [PubMed] [Google Scholar]
  13. Moss R. B., Lewiston N. J. Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. Am Rev Respir Dis. 1980 Jan;121(1):23–29. doi: 10.1164/arrd.1980.121.1.23. [DOI] [PubMed] [Google Scholar]
  14. Musher D. M., Goree A., Baughn R. E., Birdsall H. H. Immunoglobulin A from bronchopulmonary secretions blocks bactericidal and opsonizing effects of antibody to nontypable Haemophilus influenzae. Infect Immun. 1984 Jul;45(1):36–40. doi: 10.1128/iai.45.1.36-40.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ohman D. E., Chakrabarty A. M. Utilization of human respiratory secretions by mucoid Pseudomonas aeruginosa of cystic fibrosis origin. Infect Immun. 1982 Aug;37(2):662–669. doi: 10.1128/iai.37.2.662-669.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Parr D. M., Hofmann T. Loss of cryoprecipitability following proteolytic eleavage of the VH domains from a human IgG cryoglobulin. Mol Immunol. 1980 Jan;17(1):1–7. doi: 10.1016/0161-5890(80)90118-2. [DOI] [PubMed] [Google Scholar]
  17. Pedersen S. S., Espersen F., Høiby N. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol. 1987 Oct;25(10):1830–1836. doi: 10.1128/jcm.25.10.1830-1836.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pedersen S. S., Espersen F., Høiby N., Jensen T. Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. J Clin Microbiol. 1990 Apr;28(4):747–755. doi: 10.1128/jcm.28.4.747-755.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pedersen S. S., Espersen F., Høiby N., Shand G. H. Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 1989 Apr;27(4):691–699. doi: 10.1128/jcm.27.4.691-699.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pedersen S. S., Jensen T., Høiby N., Koch C., Flensborg E. W. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand. 1987 Nov;76(6):955–961. doi: 10.1111/j.1651-2227.1987.tb17271.x. [DOI] [PubMed] [Google Scholar]
  21. Petersen N. T., Høiby N., Mordhorst C. H., Lind K., Flensborg E. W., Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981 Sep;70(5):623–628. doi: 10.1111/j.1651-2227.1981.tb05757.x. [DOI] [PubMed] [Google Scholar]
  22. Piedra P., Ogra P. L. Immunologic aspects of surface infections in the lung. J Pediatr. 1986 May;108(5 Pt 2):817–823. doi: 10.1016/s0022-3476(86)80751-x. [DOI] [PubMed] [Google Scholar]
  23. Pier G. B., Desjardins D., Aguilar T., Barnard M., Speert D. P. Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Microbiol. 1986 Aug;24(2):189–196. doi: 10.1128/jcm.24.2.189-196.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schwartz R. H. Serum immunoglobulin levels in cystic fibrosis. Am J Dis Child. 1966 Apr;111(4):408–411. doi: 10.1001/archpedi.1966.02090070106015. [DOI] [PubMed] [Google Scholar]
  25. Speert D. P., Lawton D., Mutharia L. M. Antibody to Pseudomonas aeruginosa mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum. Pediatr Res. 1984 May;18(5):431–433. doi: 10.1203/00006450-198405000-00008. [DOI] [PubMed] [Google Scholar]
  26. Suter S., Schaad U. B., Roux-Lombard P., Girardin E., Grau G., Dayer J. M. Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis. 1989 Dec;140(6):1640–1644. doi: 10.1164/ajrccm/140.6.1640. [DOI] [PubMed] [Google Scholar]
  27. Szaff M., Høiby N., Flensborg E. W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983 Sep;72(5):651–657. doi: 10.1111/j.1651-2227.1983.tb09789.x. [DOI] [PubMed] [Google Scholar]
  28. Sá-Correia I., Darzins A., Wang S. K., Berry A., Chakrabarty A. M. Alginate biosynthetic enzymes in mucoid and nonmucoid Pseudomonas aeruginosa: overproduction of phosphomannose isomerase, phosphomannomutase, and GDP-mannose pyrophosphorylase by overexpression of the phosphomannose isomerase (pmi) gene. J Bacteriol. 1987 Jul;169(7):3224–3231. doi: 10.1128/jb.169.7.3224-3231.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Thomassen M. J., Demko C. A., Boxerbaum B., Stern R. C., Kuchenbrod P. J. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis. 1979 Dec;140(6):873–880. doi: 10.1093/infdis/140.6.873. [DOI] [PubMed] [Google Scholar]
  30. Wisnieski J. J., Todd E. W., Fuller R. K., Jones P. K., Dearborn D. G., Boat T. F., Naff G. B. Immune complexes and complement abnormalities in patients with cystic fibrosis. Increased mortality associated with circulating immune complexes and decreased function of the alternative complement pathway. Am Rev Respir Dis. 1985 Oct;132(4):770–776. doi: 10.1164/arrd.1985.132.4.770. [DOI] [PubMed] [Google Scholar]
  31. Wood R. E., Boat T. F., Doershuk C. F. Cystic fibrosis. Am Rev Respir Dis. 1976 Jun;113(6):833–878. doi: 10.1164/arrd.1976.113.6.833. [DOI] [PubMed] [Google Scholar]
  32. Woods D. E., Schaffer M. S., Rabin H. R., Campbell G. D., Sokol P. A. Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites. J Clin Microbiol. 1986 Aug;24(2):260–264. doi: 10.1128/jcm.24.2.260-264.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Zierdt C. H., Williams R. L. Serotyping of Pseudomonas aeruginosa isolates from patients with cystic fibrosis of the pancreas. J Clin Microbiol. 1975 Jun;1(6):521–526. doi: 10.1128/jcm.1.6.521-526.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. di Sant'agnese P. A., Davis P. B. Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature. Am J Med. 1979 Jan;66(1):121–132. doi: 10.1016/0002-9343(79)90491-1. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES